<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577808</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-R008</org_study_id>
    <nct_id>NCT03577808</nct_id>
  </id_info>
  <brief_title>Organoids in Predicting Chemoradiation Sensitivity on Rectal Cancer</brief_title>
  <official_title>Validation of Organoids Potential Use as a Companion Diagnostic in Predicting Neoadjuvant Chemoradiation Sensitivity in Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhen Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with locally advanced rectal cancer will receive biopsy before the standard&#xD;
      treatment of neoadjuvant chemoradiation. The investigators are going to establish organoids&#xD;
      model from the pre-treatment biopsies and expose organoids to irradiation and the same&#xD;
      chemotherapy drugs. The sensitivity of irradiation and chemotherapy drugs will be tested in&#xD;
      the organoids model. Here, the investigators will launch the observational clinical trial to&#xD;
      validate whether the organoids could predict the clinical outcome in locally advanced rectal&#xD;
      cancer patients underwent neoadjuvant chemoradiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 17, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response of the rectal cancer organoids to irradiation and the same chemotherapy drugs as the corresponding patient.</measure>
    <time_frame>2018.08-2020.11</time_frame>
    <description>The investigators will culture rectal cancer organoids and treat with irradiation and the same chemotherapy drugs as the corresponding patient. The number and size of alive organoids will be observed after treatment. The correlation of organoids sensitivity and patient response will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response of the rectal cancer patients to neoadjuvant chemoradiation.</measure>
    <time_frame>2018.08-2020.11</time_frame>
    <description>The investigators will use pathological tumor regression grade (TRG) to evaluate chemoradiation response of locally advanced rectal cancer patients.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Organoids</condition>
  <condition>Rectal Cancer</condition>
  <condition>Chemoradiation</condition>
  <arm_group>
    <arm_group_label>Arm</arm_group_label>
    <description>Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.</description>
    <arm_group_label>Arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The&#xD;
        radiation procedure and concurrent chemotherapy drugs will base on clinical practice.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pathological confirmed adenocarcinoma&#xD;
&#xD;
          -  clinical stage T3-4 and/or N+&#xD;
&#xD;
          -  the distance from anal verge less than 12 cm&#xD;
&#xD;
          -  without distance metastases&#xD;
&#xD;
          -  KPS &gt;=70&#xD;
&#xD;
          -  without previous anti-cancer therapy&#xD;
&#xD;
          -  sign the inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or breast-feeding women&#xD;
&#xD;
          -  serious medical illness&#xD;
&#xD;
          -  baseline blood and biochemical indicators do not meet the following criteria:&#xD;
             neutrophils≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guoqiang Hua, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Radiation Medicine, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lijun Shen, MD</last_name>
    <phone>86-2164175590</phone>
    <email>lijunshen@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhen Zhang, MD</last_name>
    <phone>86-2164175590</phone>
    <email>zhen_zhang@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun Shen, MD</last_name>
      <phone>86-2164175590</phone>
      <email>lijunshen@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhen Zhang, MD</last_name>
      <phone>86-2164175590</phone>
      <email>zhen_zhang@fudan.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhen Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guoqiang Hua, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>August 17, 2018</last_update_submitted>
  <last_update_submitted_qc>August 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhen Zhang</investigator_full_name>
    <investigator_title>Professor Zhang</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

